GlassScriptPhysician profile
Everette Barton
NPI 1235595919
$3,383.35
in general payments reported to CMS, 2019-2025
28 companies · $658 in 2025
The $658 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $412 · 2022: $539 · 2023: $857 · 2024: $917 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,381 · Education: $51.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,381.23 |
| Education | $51.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $709.29 | 2021-2025 | |
| Novo Nordisk INC | $576.62 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $449.17 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $427.84 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $248.42 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $167.91 | 2022-2023 | |
| Dexcom, INC. | $78.85 | 2023-2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $73.87 | 2022-2025 | Vyepti |
| Bayer Healthcare Pharmaceuticals INC. | $65.04 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $61.49 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $59.69 | 2022-2024 | Camzyos, Eliquis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.55 | 2025 | Caplyta |
| Pfizer INC. | $47.03 | 2023-2024 | |
| Amgen INC. | $43.48 | 2022-2024 | Repatha, Otezla |
| Astellas Pharma US INC | $38.76 | 2023-2024 | Veozah |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $37.02 | 2024-2025 | Ibsrela |
| Xeris Pharmaceuticals, INC. | $35.03 | 2021-2022 | |
| Inogen, INC. | $30.37 | 2022-2023 | Inogen At Home Stationary Concentrator |
| Takeda Pharmaceuticals U.S.A., INC. | $21.40 | 2021 | |
| Sumitomo Pharma America, INC. | $20.88 | 2023 | Gemtesa |
| Esperion Therapeutics, INC. | $20.29 | 2021 | |
| Philips North America LLC | $19.89 | 2024 | (Ck7) Extended Holter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.22 | 2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.00 | 2022 | |
| Antares Pharma, INC. | $15.23 | 2024 | Xyosted |
| Otsuka America Pharmaceutical, INC. | $14.96 | 2024 | Rexulti |
| Corcept Therapeutics | $14.53 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $13.52 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Everette Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.